Lu, P., Hu, Y., Zhang, X., Yang, J., Zhu, X., Wang, Y., Zhou, K., Wang, S., Cao, J., Mei, H., Hu, K., Yu, Y., Zhou, Y., McNulty, E., Gao, M., Delrosario, M., Ge, W., Ni, Y., Ren, J., Davidson-Moncada, J., Huang, H. (2025). CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) - report of clinical outcomes at the recommended phase 2 dose (RP2D). Blood. https://doi.org/10.1182/blood-2025-1042